Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 3,040,664
  • Shares Outstanding, K 37,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,990 K
  • 36-Month Beta 2.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.31 +11.02%
on 06/27/17
87.00 -3.90%
on 06/22/17
+0.30 (+0.36%)
since 06/21/17
3-Month
63.23 +32.23%
on 05/22/17
88.93 -5.98%
on 06/20/17
+10.79 (+14.82%)
since 04/21/17
52-Week
35.02 +138.75%
on 08/17/16
88.93 -5.98%
on 06/20/17
+40.22 (+92.69%)
since 07/21/16

Most Recent Stories

More News
Interesting SAGE Put And Call Options For February 2018

Investors in Sage Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

SAGE : 83.61 (+2.70%)
5 Top Stocks to Own

Today I sorted Barchart's Top Stocks to Own list first by the highest Weighted Alpha, then by technical buy signals of 80% or more and lastly used the FlipChart feature to review the charts...

ENZ : 11.35 (-1.05%)
TDOC : 34.40 (-0.15%)
NVTR : 12.20 (-1.37%)
SAGE : 83.61 (+2.70%)
PI : 52.41 (-2.94%)
Noteworthy Friday Option Activity: SAGE, BV, ALGN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 1,576 contracts have traded so far, representing approximately...

SAGE : 83.61 (+2.70%)
Sage Therapeutics to Present at Goldman Sachs Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.61 (+2.70%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on June...

SAGE : 83.61 (+2.70%)
Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.61 (+2.70%)
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update

--Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal

SAGE : 83.61 (+2.70%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time.

SAGE : 83.61 (+2.70%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.31 (unch)
CBAY : 7.75 (+6.16%)
SAGE : 83.61 (+2.70%)
CBIO : 4.28 (+1.42%)
BNIKF : 0.0980 (unch)
Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.61 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Support & Resistance

2nd Resistance Point 86.12
1st Resistance Point 84.86
Last Price 83.61
1st Support Level 81.74
2nd Support Level 79.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.